Is Cingulate Inc. (CING) a Buy, Sell, or Hold?
NASDAQ : CING
Cingulate Inc.
$5.25 USD
-$0.09 (-1.69%)
- Volume
- 118.09K
- Average Volume
- 459.16K
- Market Capitalization
- $29.43M
- P/E Ratio
- -1.05
- Dividend Yield
- 0.00%
- Price Target
- $10.00
- Year High
- $11.89
- Year Low
- $3.16
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.55
Company Overview
NASDAQ
Shane J. Schaffer
Biotechnology
Healthcare
CING
14
US
USD
Liquidity Metrics
0.39
2.55
2.55
2.36
0.00
Sales & Valuation
-$
0.00
1.51
-1.49
-3.64
Profitability
-$4.13
-$22.45M
0.00%
0.00%
-365.16%
-89.80%
P/E Metrics
-1.05
0.03
0.03
Analyst Price Target & Rating
$10.00
$10.00
$10.00
2/5
6 Analysts
-47.50%
Financial Health Scores
-6.85
3/9
$16.95M
$30.86M
$12M
-$24.15M
Key Metrics (TTM)
$11.47M
0.00
-0.48
2.55
-365.16%
-91.87%
-95.56%
-66.05%
0 days
Company Executives
| Name | Title |
|---|---|
| Shane J. Schaffer | Co-Founder, Chief Executive Officer & Chairman of the Board |
| Downey Bryan Wade | Executive VP & Chief Commercial Officer |
| Thomas Dalton | Vice President of Investor & Public Relations |
| Matthew N. Brams | Co-Founder, Executive Vice President & Chief Medical Officer |
| Nilay Patel | Executive VP, Chief Legal Officer & Chief Compliance Officer |
| Jennifer L. Callahan | Executive VP, CFO & Secretary |
| Raul R. Silva | Co-Founder, Executive Vice President & Chief Science Officer |
Poll Results
No votes yet today — be the first to share your view!
About Cingulate Inc. (NASDAQ:CING) Stock
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas. ...
2026-07-30 08:30:00
Publication helps establish the efficacy and safety profile of of CTx-1301, reinforcing the potential of Cingulate's Precision Timed Release™ platform technology Publication helps establish the efficacy and safety profile of of CTx-1301, reinforcing the potential of Cingulate's Precision Timed Release™ platform technology
Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®
2026-07-02 08:30:00
CEO Shane Schaffer: Inclusion Demonstrates Continued Growth and Enhanced Visibility Among Institutional Investors CEO Shane Schaffer: Inclusion Demonstrates Continued Growth and Enhanced Visibility Among Institutional Investors
Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301
2026-06-16 08:00:00
KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the issuance of its first company-owned U.S. patent covering its lead asset, CTx-1301 (dexmethylphenidate HCl), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26
2026-06-04 16:48:00
Dallas, Texas--(Newsfile Corp. - June 4, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's latest update shifts the near-term CTx-1301 setup from a PDUFA driven approval event to a CMC-driven resubmission process, while leaving the core product thesis intact based on the information disclosed.
US FDA declines to approve Cingulate's ADHD drug
2026-06-02 08:08:19
Cingulate said on Tuesday that the U.S. Food and Drug Administration declined to approve its drug to treat attention deficit hyperactivity disorder.
Cingulate Receives Complete Response Letter from FDA for CTx-1301
2026-06-02 08:00:00
No Clinical Safety or Efficacy Concerns Currently Identified Agency Feedback Primarily Focused on CMC-Related Requests Company Plans Prompt Response and Submission of Requested Information Company is Well Capitalized with Nearly $30 Million Cash on Hand KANSAS CITY, Kan., June 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today announced that the U.S. Food and Drug Administration (“FDA”) has issued a Complete Response Letter for its New Drug Application (“NDA”) for CTx-1301 (dexmethylphenidate HCl) for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD).
2026-05-14 08:00:00
KANSAS CITY, Kan., May 14, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update.
Frequently Asked Questions
-
What is the current Cingulate Inc. (CING) stock price?
-
Cingulate Inc.(NASDAQ:CING) stock price is $5.25 in the last trading session. During the trading session, CING stock reached the peak price of $11.89 while $3.16 was the lowest point it dropped to. The percentage change in CING stock occurred in the recent session was --1.69% while the dollar amount for the price change in CING stock was -$0.09.
-
CING's industry and sector of operation?
-
The NASDAQ listed CING is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CING?
-
Shane J. Schaffer | Co-Founder, Chief Executive Officer & Chairman of the Board
Downey Bryan Wade | Executive VP & Chief Commercial Officer
Thomas Dalton | Vice President of Investor & Public Relations
Matthew N. Brams | Co-Founder, Executive Vice President & Chief Medical Officer
Nilay Patel | Executive VP, Chief Legal Officer & Chief Compliance Officer -
How many employees does CING have?
-
Number of CING employees currently stands at 14. CING operates from 1901 West 47th Place, Kansas City, KS 66205, US.
-
Link for CING official website?
-
Official Website of CING is: https://www.cingulate.com
-
How do I contact CING?
-
CING could be contacted at phone #913 942 2300 and can also be accessed through its website. CING operates from 1901 West 47th Place, Kansas City, KS 66205, US.
-
How many shares of CING are traded daily?
-
The average number of CING shares traded daily for last 3 months was 459.16K.
-
What is the market cap of CING currently?
-
The market value of CING currently stands at $29.43M with its latest stock price at $5.25